fail downgrad market perform
friday april market open partner merck
announc meet one primari endpoint improv
progression-fre surviv hazard ratio co-primari endpoint
overal surviv os hazard ratio expect met either extern data
monitor committe edmc recommend studi stop safeti consist
prior observ result downgrad share outperform
market perform take epacadostat model fair valu lower
unclear whether biomark data deriv could guid phase
studi whether phase studi continu expect preliminari
analys top-lin data statu near futur biomark
includ statu tumor mutat burden rna sequenc engin
expect analys biomark correl efficaci
reveal throughout high correl biomark could identifi
subpopul hyper-respons epacadostat could lead modif data
analysi protocol phase epacadostat trial junctur unclear whether
biomark data suffici strong inform phase studi
next key catalyst share baricitinib advisori panel april data
jakafi phase ii pivot studi steroid-refractori acut gvhd first half
catalyst includ initi pivot trial jakafi essenti thrombocythemia
epacadostat keytruda nsclc rcc scchn bladder cancer itacitinib gvhd
b-cell malign dose escal data fgfr brd
pim inhibitor pair biopsi data in-hous combo
return equiti ttm
base wilmington delawar major oncology-focus biotechnolog compani
pleas refer import disclosur page analyst certif page
